A randomized, multi-center, open-label study to evaluate the efficacy and safety of Albuferon (HGS 1008, recombinant human albumin-interferon alfa fusion protein) [albinterferon alfa 2B] in combination with ribavirin in interferon alfa naive subjects with chronic hepatitis C genotype 2 or 3

Trial Profile

A randomized, multi-center, open-label study to evaluate the efficacy and safety of Albuferon (HGS 1008, recombinant human albumin-interferon alfa fusion protein) [albinterferon alfa 2B] in combination with ribavirin in interferon alfa naive subjects with chronic hepatitis C genotype 2 or 3

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Albinterferon alfa 2B; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 30 Jan 2013 Trial association changed from Human Genome Sciences to GlaxoSmithKline, as Human Genome Sciences acquired by GlaxoSmithKline.
    • 03 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top